Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma.
The evaluation of minimal residual disease (MRD) is critical in the evaluation of treatments aimed at maximal cytoreduction in multiple myeloma (MM). Qualitative evaluation of MRD now has a 10-yr-long history, but it remains a relatively sophisticated procedure. More recently, real-time quantitative approaches have also been developed. These approaches allow a very effective monitoring of disease but introduce additional complexity and costs to the procedure. This chapter describes how we currently perform real-time polymerase chain reaction (PCR) in MM. Compared to the first description of the assay in June 2000, significant improvements have been made. Although real-time PCR is the main focus of the chapter, most of the information suitable for a proper setup of a qualitative approach is also provided.
Compagno
Mara
M
Divisione di Ematologia, Universita' di Torino, Torno, Italy.
Mantoan
Barbara
B
Astolfi
Monica
M
Boccadoro
Mario
M
Ladetto
Marco
M
D001483:Base Sequence; D017931:DNA Primers; D004273:DNA, Neoplasm / Q000737:chemistry / Q000235:genetics; D015321:Gene Rearrangement; D006801:Humans; D007136:Immunoglobulins / Q000235:genetics*; D007621:Karyotyping / Q000379:methods; D009101:Multiple Myeloma / Q000175:diagnosis / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D018365:Neoplasm, Residual / Q000175:diagnosis* / Q000235:genetics / Q000276:immunology; D009690:Nucleic Acid Conformation; D016133:Polymerase Chain Reaction / Q000379:methods
D017931:DNA Primers; D004273:DNA, Neoplasm; D007136:Immunoglobulins